Amneal Pharmaceuticals is trading 10.85% up at $20.74 after FDA approval and immediate U.S. launch of generic lanreotide injection on September 18, 2026.
- The 120 mg/0.5 mL injection references Somatuline Depot and received Competitive Generic Therapy designation.
- The product targets acromegaly, neuroendocrine tumors, and carcinoid syndrome.
- Broader risk-on markets may provide additional support, but the FDA announcement is the primary driver.